Cluster 5 (in purple) includes the keywords “trastuzumab”, “growth”, “open-label”, “HER2” and “targeted therapy”, exploring clinical trials related to HER2-positive breast cancer treatment, such as antibody-drug conjugates, tyrosine kinase inhibitors and HER2-targeted monoclonal antibodies. Here, ERBB2 is linked to breast cancer.